Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Leoncikas, Vytautas ^a   Wu, Huihai ^a   Ward, Lara T ^b   Kierzek, Andrzej M ^a   Plant, Nick J ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN; TRANSCRIPTOME; TUMOR MARKER;

BIOLOGICAL MODEL; BIOLOGY; BIOSYNTHESIS; BREAST TUMOR; CLUSTER ANALYSIS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; METABOLOME; METABOLOMICS; MORTALITY; PROCEDURES; PROGNOSIS; TUMOR CELL LINE;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; METABOLOME; METABOLOMICS; MODELS, BIOLOGICAL; PROGNOSIS; SEROTONIN; TRANSCRIPTOME;

EID: 84955481568     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19771     Document Type: Article

References (55)

1. Weigelt, B. et al. Breast cancer molecular profiling with single sample predictors: A retrospective analysis. Lancet Oncol. 11, 339-349, doi: 10.1016/s1470-2045(10)70008-5 (2010).
2. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352, doi: 10.1038/nature10983 (2012).
3. Colombo, P.-E., Milanezi, F., Weigelt, B. & Reis-Filho, J. S. Microarrays in the 2010s: The contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res. 13, 212, doi: 10.1186/bcr2890 (2011).
4. Reis-Filho, J. S. & Pusztai, L. Breast Cancer 2 Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 378, 1812-1823 (2011).
5. Crown, J., O'Shaughnessy, J. & Gullo, G. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 23, 56-65, doi: 10.1093/annonc/mds196 (2012).
6. Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108-1115, doi: 10.1038/nmeth.2651 (2013).
7. Chuang, H.-Y., Lee, E., Liu, Y.-T., Lee, D. & Ideker, T. Network-based classification of breast cancer metastasis. Mol. Sys. Biol. 3, 140, doi: 10.1038/msb4100180 (2007).
8. Plant, N. J. An introduction to systems toxicology. Toxicol. Res. 4, 9-22, doi: 10.1039/c4tx00058g (2015).
9. Bordbar, A., Monk, J. M., King, Z. A. & Palsson, B. O. Constraint-based models predict metabolic and associated cellular functions. Nat. Rev. Genet. 15, 107-120, doi: 10.1038/nrg3643 (2014).
10. Orth, J. D., Thiele, I. & Palsson, B. O. What is flux balance analysis? Nat. Biotechnol. 28, 245-248, doi: 10.1038/nbt.1614 (2010).
11. Thiele, I. et al. A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 31, 419, doi:10.1038/nbt.2488 (2013).
12. Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. P.N.A.S. 104, 1777-1782, doi: 10.1073/pnas.0610772104 (2007).
13. Yizhak, K. et al. Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. Elife 3, e03641, doi: 10.7554/eLife.03641 (2014).
14. Yizhak, K., Chaneton, B., Gottlieb, E. & Ruppin, E. Modeling cancer metabolism on a genome scale. Mol. Sys. Biol. 11, 817-817, doi: 10.15252/msb.20145307 (2015).
15. Donoghue, M. et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circul. Res. 87, E1-E9 (2000).
16. Vickers, C. et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843, doi: 10.1074/jbc.M200581200 (2002).
17. Kampa, M. et al. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur. J. Pharmacol. 335, 255-265, doi: 10.1016/s0014-2999(97)01213-2 (1997).
18. Hatzoglou, A., Bakogeorgou, E., Hatzoglou, C., Martin, P. M. & Castanas, E. Antiproliferative and receptor binding properties of alpha-and beta-casomorphins in the T47D human breast cancer cell line. Eur. J. Pharmacol. 310, 217-223, doi: 10.1016/0014-2999(96)00339-1 (1996).
19. Stirnweiss, J. et al. Tyr-c D-Orn-Tyr(Bzl)-Pro-Gly : A novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties. Br. J. Pharmacol. 140, 13-22, doi: 10.1038/sj.bjp.0705416 (2003).
20. Stork, P. J. S. & Schmitt, J. M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12, 258-266, doi: 10.1016/s0962-8924(02)02294-8 (2002).
21. Gach, K., Wyrebska, A., Fichna, J. & Janecka, A. The role of morphine in regulation of cancer cell growth. Naunyn-Schmiedeberg's Arch. Pharmacol. 384, 221-230, doi: 10.1007/s00210-011-0672-4 (2011).
22. Bimonte, S., Barbieri, A., Palma, G. & Arra, C. The Role of Morphine in Animal Models of Human Cancer: Does Morphine Promote or Inhibit the Tumor Growth? Biomed. Res. Int., 258141, doi: 10.1155/2013/258141 (2013).
23. Chae, Y. K. et al. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J. Cancer 4, 549-556, doi: 10.7150/jca.6888 (2013).
24. Kwok, W. H. et al. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 405, 2595-2606, doi: 10.1007/s00216-012-6697-9 (2013).
25. Ba, H.-J. et al. Associations between Serum Apelin-12 Levels and Obesity-Related Markers in Chinese Children. Plos One 9, e86577, doi: 10.1371/journal.pone.0086577 (2014).
26. Wang, Z. et al. Separation and determination of beta-casomorphins by using glass microfluidic chip electrophoresis together with laser-induced fluorescence detection. J. Sep. Sci. 34, 196-201, doi: 10.1002/jssc.201000634 (2011).
27. Matsuda, M. et al. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev. Cell 6, 193-203, doi: 10.1016/s1534-5807(04)00022-x (2004).
28. Froebe, A. et al. Plasma Free Serotonin as a Marker for Early Detection of Breast Cancer Recurrence. Anticancer Research 34, 1167-1169 (2014).
29. Lee, M. S., Cheng, F. C., Yeh, H. Z., Liou, T. Y. & Liu, J. H. Determination of plasma serotonin and 5-hydroxyindoleacetic acid in healthy subjects and cancer patients. Clin. Chem. 46, 422-423 (2000).
30. Jungwirth, N., Haeberle, L., Schrott, K. M., Wullich, B. & Krause, F. S. Serotonin used as prognostic marker of urological tumors. World J. Urol. 26, 499-504, doi: 10.1007/s00345-008-0285-9 (2008).
31. Subik, K. et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer 4, 35-41 (2010).
32. Gilbert, J. A., Frederick, L. M. & Ames, M. M. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin. Cancer Res. 6, 4365-4372 (2000).
33. Pai, V. P., Marshall, A. M., Hernandez, L. L., Buckley, A. R. & Horseman, N. D. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 11, R81, doi: 10.1186/bcr2448 (2009).
34. Sarrouilhe, D., Clarhaut, J., Defamie, N. & Mesnil, M. Serotonin and Cancer: What is the Link? Curr. Mol. Med. 15, 62-77 (2015).
35. Shinka, T. et al. Serotonin synthesis and metabolism-related molecules in a human prostate cancer cell line. Oncol. Lett. 2, 211-215, doi: 10.3892/ol.2011.244 (2011).
36. Wishart, D. S. et al. HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res. 41, D801-D807, doi: 10.1093/nar/gks1065 (2013).
37. Hen, R. Of mice and flies-commonalities among 5-HT receptors. Trends Pharmacol. Sci. 13, 160-165, doi: 10.1016/0165-6147(92)90054-a (1992).
38. Gonzalez, G. A. & Montminy, M. R. Cyclic-AMP stimulates somastostatin gene trasnscription by phosphorylation of CREB at Serine-133. Cell 59, 675-680, doi: 10.1016/0092-8674(89)90013-5 (1989).
39. Rubinfeld, H. & Seger, R. The ERK cascade-A prototype of MAPK signaling. Mol. Biotechnol. 31, 151-174, doi: 10.1385/mb:31:2:151 (2005).
40. Kwidzinski, E. & Bechmann, I. IDO expression in the brain: A double-edged sword. J. Mol. Med. 85, 1351-1359, doi: 10.1007/s00109-007-0229-7 (2007).
41. Demopoulos, C. A., Pinckard, R. N. & Hanahan, D. J. Platelet-activating factor-evidence for 1-o-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J. Biol. Chem. 254, 9355-9358 (1979).
42. Kelly, C. M. et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. B.M.J. 340, c693, doi: 10.1136/bmj.c693 (2010).
43. Kelly, J. P. et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am. J. Epidemiol. 150, 861-868 (1999).
44. Cosgrove, L. et al. Antidepressants and Breast and Ovarian Cancer Risk: A Review of the Literature and Researchers' Financial Associations with Industry. Plos One 6, e18210, doi: 10.1371/journal.pone.0018210 (2011).
45. Eom, C.-S., Park, S. M. & Cho, K.-H. Use of antidepressants and the risk of breast cancer: A meta-analysis. Breast Cancer Res. Treat. 136, 635-645, doi: 10.1007/s10549-012-2307-y (2012).
46. Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N. & Karamanos, N. K. Proteoglycans in health and disease: Novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 277, 3904-3923, doi: 10.1111/j.1742-4658.2010.07800.x (2010).
47. Potapenko, I. O. et al. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Molecular Oncology 4, 98-118, doi: 10.1016/j.molonc.2009.12.001 (2010).
48. Pothacharoen, P. et al. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J. Biochem. 140, 517-524, doi: 10.1093/jb/mvj181 (2006).
49. Sethi, S., Ali, S., Philip, P. A. & Sarkar, F. H. Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy. Int. J. Mol. Sci. 14, 14771-14784, doi: 10.3390/ijms140714771 (2013).
50. Fuster, M. M. & Esko, J. D. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526-542, doi: 10.1038/nrc1649 (2005).
51. Dennis , G. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, R60. (2003).
52. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70, doi: 10.1016/s0092-8674(00)81683-9 (2000).
53. Shlomi, T., Cabili, M. N., Herrgard, M. J., Palsson, B. O. & Ruppin, E. Network-based prediction of human tissue-specific metabolism. Nat. Biotechnol. 26, 1003-1010, doi: 10.1038/nbt.1487 (2008).
54. Gevorgyan, A., Bushell, M. E., Avignone-Rossa, C. & Kierzek, A. M. SurreyFBA: A command line tool and graphics user interface for constraint-based modeling of genome-scale metabolic reaction networks. Bioinformatics 27, 433-434, doi: 10.1093/bioinformatics/btq679 (2011).
55. Gentleman, R. C. et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).